首页> 外文期刊>Vaccine >Induction of Gag-specific T-cell responses by therapeutic immunization with a Gag-expressing Sendai virus vector in macaques chronically infected with simian-human immunodeficiency virus
【24h】

Induction of Gag-specific T-cell responses by therapeutic immunization with a Gag-expressing Sendai virus vector in macaques chronically infected with simian-human immunodeficiency virus

机译:在患有猿猴-人免疫缺陷病毒的慢性猕猴中,用表达Gag的仙台病毒载体进行治疗性免疫,诱导Gag特异性T细胞应答

获取原文
获取原文并翻译 | 示例
           

摘要

Recent prophylactic vaccine trials inducing virus-specific CD8+ T-cell responses have shown control of primary infections of a pathogenic simian-human immunodeficiency virus (SHIV) in macaques. In the chronic phase, therapeutic immunization replenishing virus-specific CD8+ T-cells is likely to contribute to sustained control of virus replication. In this study, we have administered a recombinant Sendai virus (SeV) vector into five rhesus macaques that had received prophylactic vaccinations and had controlled SHIV replication for more than 1 year after challenge. Our results indicate that virus-specific CD8+ T-cell responses can be expanded and broadened by therapeutic immunization with SeV vectors in the chronic phase after prophylactic vaccine-based control of primary immunodeficiency virus infections.
机译:近期诱导病毒特异性CD8 + T细胞反应的预防性疫苗试验显示,猕猴中原发性猿猴-人免疫缺陷病毒(SHIV)的原发感染得到控制。在慢性期,补充病毒特异性CD8 + T细胞的治疗性免疫可能有助于持续控制病毒复制。在这项研究中,我们已将重组仙台病毒(SeV)载体施用于五只猕猴,这些猕猴接受了预防性疫苗接种并在攻击后控制SHIV复制超过1年。我们的结果表明,在基于预防性疫苗的原发性免疫缺陷病毒感染控制后的慢性期,通过用SeV载体进行治疗性免疫,可以扩展和扩大病毒特异性CD8 + T细胞应答。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号